Indinavir trough concentration as a determinant of early nephrolithiasis in HIV-1-infected adults

Therapeutic Drug Monitoring

Volumn 29, Issue 2, 2007, Pages 164-170

  Collin, Fidéline ^a,b   Chêne, Geneviève ^a,b   Retout, Sylvie ^a,c,d   Peytavin, Gilles ^c   Salmon, Dominique ^e   Bouvet, Elisabeth ^c   Raffi, François ^f   Garraffo, Rodolphe ^g   Mentré, France ^a,c,d   Duval, Xavier ^c   Leport, C ^h   Raffi, F ^h   Chene G ^h   Salamon, R ^h   Moatti, J P ^h   Pierret, J ^h   Spire, B ^h   Brun Vezinet F ^h   Fleury, H ^h   Masquelier, B ^h   Peytavin, G ^h   Garraffo, R ^h   more..

^a INSERM   (France)

^b UNIVERSITÉ DE BORDEAUX   (France)

^c BICHAT HOSPITAL   (France)

^d UNIVERSITÉ PARIS DESCARTES   (France)

^e Université Paris VII ^*  (France)

^f HÔTEL DIEU   (France)

^g PASTEUR HOSPITAL   (France)

^h Hôpital Hôtel Dieu ^*

Author keywords

Indinavir; Nephrolithiasis; Pharmacokinetic; Plasma levels; Toxicity

Indexed keywords

DIDANOSINE; INDINAVIR; LAMIVUDINE; STAVUDINE; ZALCITABINE; ZIDOVUDINE;

ADULT; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; COHORT ANALYSIS; CONFIDENCE INTERVAL; CONTROLLED STUDY; DIABETES MELLITUS; DRUG BLOOD LEVEL; FEMALE; FOLLOW UP; HAZARD RATIO; HEPATIC CYTOLYSIS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERGLYCEMIA; MALE; MAXIMUM PLASMA CONCENTRATION; MULTIVARIATE ANALYSIS; NEPHROLITHIASIS; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL;

ADULT; AGE FACTORS; AREA UNDER CURVE; FEMALE; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; INDINAVIR; MALE; NEPHROLITHIASIS; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES;

EID: 34248230210     PISSN: 01634356     EISSN: None     Source Type: Journal    
DOI: 10.1097/ftd.0b013e318030839e     Document Type: Article

References (38)

1. Duval X, Journot V, Leport C, et al. Incidence and determinants of severe adverse reaction in a prospective cohort of HIV infected adults started on a protease inhibitor-containing therapy. Clin Infect Dis. 2004;39:248-255.
2. Bonfanti P, Ricci E, Landonio S, et al. Predictors of protease inhibitor-associated adverse events. Biomed Pharmacother. 2001;55:321-323.
3. Abad-Santos F, Carcas AJ, Ibanez C, et al. Digoxin level and clinical manifestations as determinants in the diagnosis of digoxin toxicity. Ther Drug Monit. 2000;22:163-168.
4. McMaster P, Mirza DF, Ismail T, et al. Therapeutic drug monitoring of tacrolimus in clinical transplantation. Ther Drug Monit. 1995;17:602-605.
5. Lyass O, Uziely B, Ben-Yosef R, et al. Correlation of toxicity with pharmacokinetics of pegylated liposomal doxorubicin (Doxil) in metastatic breast carcinoma. Cancer. 2000;89:1037-1047.
6. Crixivan (indinavir sulfate) product monograph. West Point, PA: Merck Co Inc; 1997.
7. Murphy RL, Sommadossi JP, Lamson M, et al. Antiviral effect and pharmacokinetic interaction between nevirapine and indinavir in persons infected with human immunodeficiency virus type 1. J Infect Dis. 1999;179:1116-1123.
8. Durant J, Clevenbergh P, Garraffo R, et al. Importance of protease inhibitor plasma levels in HIV-infected patients treated with genotypic-guided therapy: pharmacological data from the Viradapt Study. AIDS. 2000;14:1333-1339.
9. Acosta EP, Henry K, Baken L, et al. Indinavir concentrations and antiviral effect. Pharmacotherapy. 1999;19:708-712.
10. Burger DM, Hugen PW, Aarnoutse RE, et al. Treatment failure of nelfinavir-containing triple therapy can largely be explained by low nelfinavir plasma concentrations. Ther Drug Monit. 2003;25:73-80.
11. Duval X, Mentre F, Lamotte C, et al. Indinavir plasma concentration and adherence score are codeterminant of early virologic response in HIV-infected patients of the APROCO cohort. Ther Drug Monit. 2005;27:63-70.
12. Woolf E, Au T, Haddix H, et al. Determination of L-735 524, an human immunodeficiency virus protease inhibitor, in human plasma and urine via high-performance liquid chromatography with column switching. J Chromatogr A. 1995;692:45-52.
13. Aymard G, Legrand M, Trichereau N, et al. Determination of twelve antiretroviral agents in human plasma sample using reversed-phase high-performance liquid chromatography. J Chromatogr B Biomed Sci Appl. 2000;744:227-240.
14. Brendel K, Legrand M, Taburet AM, et al. Population pharmacokinetic analysis of indinavir in HIV-infected patient treated with a stable antiretroviral therapy. Fundam Clin Pharmacol. 2005;19:373-383.
15. Mandema J, Welling PG, Tse FLS. Population pharmacokinetics and pharmacodynamics. In: Pharmacokinetics: Regulatory, Industrial, Academic Perspectives. New York: Library of Congress; 1995:411-449.
16. Racine-Poon A, Wakefield J. Statistical methods for population pharmacokinetic modelling. 1998;7:63-84.
17. Clinical safety data management: definitions and standards for expedited reporting. Federal Register. 1995;60:11284-11287.
18. Boubaker K, Sudre P, Bally F, et al. Changes in renal function associated with indinavir. AIDS. 1998;12:F249-254.
19. Brodie SB, Keller MJ, Ewenstein BM, et al. Variation in incidence of indinavir-associated nephrolithiasis among HIV-positive patients. AIDS. 1998;12:2433-2437.
20. Dieleman JP, Gyssens IC, van der Ende ME, et al. Urological complaints in relation to indinavir plasma concentrations in HIV-infected patients. AIDS. 1999;13:473-478.
21. Flexner C. HIV-protease inhibitors. N Engl J Med. 1998;338:1281-1292.
22. Kopp JB, Miller KD, Mican JA, et al. Crystalluria and urinary tract abnormalities associated with indinavir. Ann Intern Med. 1997;127:119-125.
23. Plosker GL NS. Indinavir: a review of its use in the management of HIV infection. Drugs. 1999;58:1165-1203.
24. Burger DM, Siebers MC, Hugen PW, et al. Pharmacokinetic variability caused by gender: do women have higher indinavir exposure than men? J Acquir Immune Defic Syndr. 2002;29:101-102.
25. Bonfanti P, Valsecchi L, Parazzini F, et al. Incidence of adverse reactions in HIV patients treated with protease inhibitors: a cohort study. Coordinamento Italiano Studio Allergia e Infezione da HIV (CISAI) Group. J Acquir Immune Defic Syndr. 2000;23:236-245.
26. Kirk O, Gerstoft J, Pedersen C, et al. Low body weight and type of protease inhibitor predict discontinuation and treatment-limiting adverse drug reactions among HIV-infected patients starting a protease inhibitor regimen: consistent results from a randomized trial and an observational cohort. HIV Med. 2001;2:43-51.
27. Gehan EA, George SL. Estimation of human body surface area from height and weight. Cancer Chemother Rep. 1970;54:225-235.
28. Carr A, Cooper D. Adverse effects of antiretroviral therapy. Lancet. 2000;356:1423-1430.
29. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16:31-41.
30. Duval X, Peytavin G, Albert I, et al. Determination of indinavir and nelfinavir trough plasma concentration efficacy thresholds according to virological response in HIV-infected patients. HIV Med. 2004;5:307-313.
31. Mazumdar M, Smith A, Bacik J. Methods for categorizing a prognostic variable in a multivariable setting. Stat Med. 2003;22:559-571.
32. Martinez E, Leguizamon M, Mallolas J, et al. Influence of environmental temperature on incidence of indinavir-related nephrolithiasis. Clin Infect Dis. 1999;29:422-425.
33. min is associated with higher toxicity in patients on indinavir-ritonavir 800/100 mg twice-daily regimen. J Acquir Immune Defic Syndr. 2002;29:374-377.
34. Gatti G, Di Biagio A, Casazza R, et al. The relationship between ritonavir plasma levels and side-effects: implications for therapeutic drug monitoring. AIDS. 1999;13:2083-2089.
35. Khoo S, Gibbons S, Back D. Therapeutic drug monitoring as a tool in treating HIV infection. AIDS. 2001;15(Suppl 5):S171-S181.
36. Rayner CR, Galbraith KJ, Marriott JL, et al. A critical evaluation of the therapeutic range of indinavir. Ann Pharmacother. 2002;36:1230-1237.
37. Marzolini C, Telenti A, Decosterd LA, et al. Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients. AIDS. 2001;15:71-75.
38. Burger D, Hugen P, Reiss P, et al. Therapeutic drug monitoring of nelfinavir and indinavir in treatment-naive HIV-1-infected individuals. AIDS. 2003;17:1157-1165.